![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Roche’s Tecentriq Gets Breakthrough Therapy Status
Roche’s Tecentriq Gets Breakthrough Therapy Status
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
July 23, 2018
The FDA granted a breakthrough therapy designation to Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) to treat hepatocellular carcinoma.
The approval covers first-line treatment for patients with advanced or metastatic HCC.
The decision marks Roche’s third breakthrough therapy designation for Tecentriq. Another study investigating the combination of Tecentriq and Avastin versus sorafenib is currently under way.
Upcoming Events
-
21Oct